|
WO2020257279A1
|
|
Combination treatments for central nervous system disorders
|
|
AU2016203655A1
|
|
Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits
|
|
AU2013206632A1
|
|
Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits
|
|
CA3011023A1
|
|
Composition comprising triethylenetramine salts for treating tissue damage
|
|
CA2828595A1
|
|
Use of copper chelating tetraamines for the treatment of cardiovascular disease and heart failure
|
|
EP2500018A1
|
|
Preventing and/or Treating Cardiovascular Disease and/or Associated Heart Failure
|
|
EP1115389A1
|
|
Fructosamine oxidase: antagonists and inhibitors
|
